Department of Thoracic and Cardiovascular Surgery, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
Ann Thorac Surg. 2013 Aug;96(2):535-41. doi: 10.1016/j.athoracsur.2013.03.004. Epub 2013 Apr 23.
Second-generation drug-eluting stents (DESs) are known to have better safety and clinical outcomes compared with the first-generation DESs. We compared the clinical results of off-pump coronary artery bypass grafting (OPCAB) with percutaneous coronary intervention (PCI) using second-generation DESs.
The study enrolled 1,821 patients with triple-vessel or left main coronary disease, or both, who underwent OPCAB or PCI with second-generation DESs from 2008 to 2011. Major adverse cardiac and cerebrovascular events (MACCEs), including death, myocardial infarction, stroke, and target vessel revascularization, were retrospectively compared between the two groups in a real-world and in a matched population (n = 1,294). Follow-up duration was 23.0 ± 13.0 months (range, 0 to 56 months).
The postprocedural mortality rate was comparable between the two groups (p = 0.384). The overall rate of MAACEs was 7.3% in the PCI group and 3.8% in the OPCAB group (p = 0.001). The 3-year rate of freedom from MACCEs was 88.4% ± 1.5% in the PCI group and 94.9% ± 1.0% in the OPCAB group (p < 0.001). In a matched population comparison, the 3-year rate of freedom from a MACCE was 87.5% ± 2.0% in the PCI group and 95.3% ± 1.2% in the OPCAB group (p = 0.001). The determining factors were nonfatal myocardial infarction and target vessel revascularization. The OPCAB group showed a superior rate of freedom from MACCEs in the triple-vessel (p = 0.008) and left main subset analysis (p = 0.001).
The OPCAB showed superior outcomes in triple-vessel or left main disease, or both, compared with PCI in the second-generation DES era after 23 months of follow-up. Nonfatal myocardial infarction and target vessel revascularization were the determining factors. Longer follow-up with randomization will clarify our results.
与第一代药物洗脱支架(DES)相比,第二代 DES 具有更好的安全性和临床结果。我们比较了使用第二代 DES 的非体外循环冠状动脉旁路移植术(OPCAB)与经皮冠状动脉介入治疗(PCI)的临床结果。
本研究纳入了 2008 年至 2011 年间接受 OPCAB 或 PCI 并使用第二代 DES 的 1821 例三支血管或左主干病变或两者均有的患者。在真实世界和匹配人群(n=1294)中,回顾性比较两组之间的主要不良心脑血管事件(MACCE),包括死亡、心肌梗死、卒中和靶血管血运重建。随访时间为 23.0±13.0 个月(范围 0 至 56 个月)。
两组术后死亡率相当(p=0.384)。PCI 组 MACCE 总发生率为 7.3%,OPCAB 组为 3.8%(p=0.001)。PCI 组 3 年 MACCE 无事件生存率为 88.4%±1.5%,OPCAB 组为 94.9%±1.0%(p<0.001)。在匹配人群比较中,PCI 组 3 年 MACCE 无事件生存率为 87.5%±2.0%,OPCAB 组为 95.3%±1.2%(p=0.001)。决定因素是非致死性心肌梗死和靶血管血运重建。OPCAB 在第三代 DES 时代,23 个月随访后,在三支血管(p=0.008)和左主干亚组分析(p=0.001)中显示出更好的 MACCE 无事件生存率。
在第二代 DES 时代,与 PCI 相比,OPCAB 在 23 个月的随访后在三支血管或左主干病变或两者均有患者中显示出更好的结果。非致死性心肌梗死和靶血管血运重建是决定因素。更长时间的随机随访将阐明我们的结果。